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Over  the  last  35 years,  efforts  at the National  Institutes  of  Health  (NIH)  to protect  mothers  and  their
infants  against  infectious  diseases  have  involved  a bench-to-bedside  approach.  Basic  and  translational
research  that  provided  a foundation  for clinical  trials  of  vaccines  in  pregnancy  include  natural  history  and
vaccine antigen  identiﬁcation  studies.  Development  of laboratory  assays  and  reagents  have  been  funded
by NIAID;  these  are  critical  for the  advancement  of vaccine  candidates  through  the  preclinical  and  clinical
steps  along  the maternal  immunization  research  pathway  to support  vaccine  efﬁcacy.  Animal  models  of
maternal  immunization  have  been  developed  to evaluate  efﬁcacy  of vaccine  candidates.  Clinical  studies
required  development  of  maternal  immunization  protocols  to  address  speciﬁc  pregnancy  related  issues,
for enrollment  and safety  assessment  of  mothers  and  their  infants.  NIH has  organized  and  participated
in  meetings,  workshops  and  other  collaborative  efforts  with  partners  have  advanced  maternal  immu-
nization  efforts.  Partners  have  included  many  institutes  and  ofﬁces  at NIH as  well  as  other  Department
of  Health  and  Human  Services  agencies  and  ofﬁces  (Food  and  Drug  Administration,  Centers  for  Disease
Control  and  Prevention,  National  Vaccine  Program  Ofﬁce),  World  Health  Organization,  academic  investi-
gators,  Biotech  and  pharmaceutical  companies,  and  nonproﬁt  organizations  such  as the  Bill  and  Melinda
Gates  Foundation.  These  research  and  development  partnership  are essential  for advancing  maternal
immunization.  Continued  efforts  are  needed  to promote  maternal  immunization  to protect  pregnant
women  and  their  infants  against  vaccine-preventable  infectious  disease,  especially  in  resource-limited
settings  where  the  burden  of infections  is  high.
ublis©  2015  The  Authors.  P
. Introduction
Efforts at the National Institutes of Health (NIH) to protect
others and their infants against infectious diseases have involved
 bench-to-bedside approach. Basic and translational research
as provided a foundation for clinical studies with investiga-
ional and licensed vaccines. These studies assessed the safety
nd immunogenicity of vaccines in pregnant women  and their
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children. Additional research is ongoing which has the potential
to impact maternal immunization by informing policy and product
development.
While comprehensive review of each study supported over the
past 35 years would have been one approach, the purpose of this
review is to highlight several types of nonclinical and clinical stud-
ies that led to a better understanding of responses to vaccines
administered during pregnancy. Selected NIH supported clinical
trials are presented in Table 1.
At the National Institute of Allergy and Infectious Diseases
(NIAID) all of the above efforts were funded via grants, contracts
and interagency agreements with other government agencies. The
breath of the program is demonstrated by diversity of agents and
products tested. Studies of vaccines to protect infants against infec-
tions caused by Streptococcus pneumoniae, group B Streptococcus
(GBS), Bordetella pertussis, Haemophilus inﬂuenzae type b (Hib),
respiratory syncytial virus (RSV), seasonal and pandemic inﬂuenza
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table  1
Selected NIH vaccine studies in pregnant women  and their infants.
Vaccine target Product Population Immunogenicity Persistence of maternal
antibodies in infant blood or
relevant information if only
infant sample was cord blood
Ref.
Group B
Streptococcusa
GBS III capsular
polysaccharide vaccine
40 pregnant women Immune response rate of 63%,
comparable to a study with
non- pregnant adults
3 months of age [5]
GBS III-TT conjugate 30 pregnant women
randomized 2:1
vaccine:saline placebo
Immune response in 95%
comparable to non-pregnant
women who received same
dose and lot of vaccine
2 months of age [7]
RSVa RSV puriﬁed fusion
protein-2 (PFP-2)
vaccine
(Wyeth-Lederle
Vaccines)
35 pregnant women
randomized 4:3
vaccine:saline placebo
Immune response in vaccine
recipients: 75% by Western
Blot and 95% by ELISA
2 and 6 months of age [2]
Pneumo/Hiba Haemophilus inﬂuenzae
type b conjugate
(HbOC, HibTITER,
Lederle Praxis
Laboratories) and
23-valent
pneumococcal
polysaccharide vaccine
(PSV, Pneumovax 23,
Merck and Co)
60 pregnant women
randomized 2:1
HbOC:PSV
Concentrations of maternal
antibody to common
pneumococcal serotypes were
signiﬁcantly higher at delivery
in PVC immunized mothers
versus HbOC immunized
mothers
2 and 7 months of age
(pneumococcal Ab, varied with
serotype)
2 months of age (Hib Ab)
Presence of maternally derived
anti-PRP did not interfere with
the infant’s immune response
to routine immunization to Hib
[10,11]
Pneumoa,b 9 valent pneumococcal
conjugate vaccine
(PVC-9, Wyeth Lederle)
152 pregnant women
randomized 1:1
vaccine:saline placebo
Signiﬁcantly higher type
speciﬁc pneumococcal
antibodies in mothers
receiving PVC-9 compared to
controls at delivery and 2, 6
and 13 months post
vaccination
Immunization of mothers with
PVC-9 correlated with
decreased infant antibody
responses to some vaccine
serotypes (routine
immunization with Prevnar)
[35]
Hiba Capsular
polysaccharide (PRP)
vaccine of Haemophilus
inﬂuenzae tybe b
213 pregnant women
randomized to receive
PRP or saline placebo
Cord samples from 75
deliveries (35 from PRP
group and 40 from
placebo group)
Infants born to PRP recipients
had signiﬁcantly higher levels
of antibody to PRP than infants
born to placebo recipients
Estimated that infants of PRP
recipients would be protected
for average of 4 months
compared to two months for
infants from placebo controls
[8]
Hiba Hib polysaccharide PRP
(HIB-immune, Lederle
Labs) Hib conjugate
PRP-D (ProHIBiT,
Connaught)
Hib conjugate HbOC
(HibTITER, Lederle
Praxis Laboratories)
50 pregnant women
randomized to receive
PRP [13]; PRP-D [19]
and PRP-HbOC [18]
47 unimmunized
pregnant women
Mothers who received any Hib
vaccine had signiﬁcantly
higher anti-PRP antibodies
than unimmunized women.
Women  who received Hib
conjugate vaccines had higher
levels than women  who
receive PRP vaccine.
Protective PRP antibody level
in cord specimens from all
infants of immunized mothers
compared with 60% of
unimmunized controls.
[9]
Pertussisa Adacel® (Sanoﬁ
Pasteur, Tdap) Tetanus
toxoid, reduced
diphtheria toxoid and
acellular pertussis
(Tdap) vaccine
48 pregnant women
randomized 2:1,
vaccine: saline placebo
with crossover
immunization
postpartum
32 age matched non-
pregnant women  (Tdap
open label)
Signiﬁcantly higher
concentrations of pertussis
antibodies at birth and 2
months of age following
antepartum versus postpartum
vaccination.
2 months of age
Pertussis antibody responses in
infants born to women
receiving Tdap during
pregnancy were not different
following the fourth dose of
DTaP
[20]
Trivalent inﬂuenzaa Trivalent inﬂuenza
vaccine (TIV)
(Connaught
Laboratories)
Tetanus toxoid vaccine
(TT) (Connaught
Laboratories)
30 pregnant women
randomized 1:1 TIV:TT
Maternal seroconversion to
one or more vaccine antigens
in all TIV recipients and 9/13
TT recipients
2 months of age [36]
Trivalent inﬂuenzac Trivalent Inﬂuenza
vaccines and
monovalent H1N1
adminstered as part of
routine clinical care
239 pregnant and
postpartum women
Observational cohort
4 consecutive inﬂuenza
vaccination seasons
Adequate seroconversion rates
demonstrated during
pregnancy and postpartum
period.
Seroconversion rates lowest in
ﬁrst trimester (54.8%) and
immediate postpartum (54.8%)
and highest in late third
trimester (69.6%) and late
postpartum (69.4%).
Not applicable as no infant
blood samples collected.
[37]
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Table 1 (Continued)
Vaccine target Product Population Immunogenicity Persistence of maternal
antibodies in infant blood or
relevant information if only
infant sample was cord blood
Ref.
Trivalent inﬂuenzaa 2008/2009 trivalent
inﬂuenza vaccine
Fluzone® (Sanoﬁ
Pasteur) Fluarix®
(GlaxoSmithKline)
102 pregnant women
randomized 1:1
Fluzone:Fluarix
Immune responses similar to
those achieved in
non-pregnant women.
Not applicable as no infant
blood samples were collected.
[38]
2009 H1N1a H1N1 vaccine
hemagglutinin (HA)
(Sanoﬁ Pasteur)
120 pregnant women
randomized 1:1 to 2
doses of 25 g or 2
doses of 49 g HA
administered 21 days
apart
One dose of vaccine was  highly
immunogenic with 93%
seroprotection after one dose
of 25 g HA and 97%
seroprotection after one dose
of 49 g HA
Not applicable as only infant
sample collected was  cord
blood.
[39]
2009 H1N1d pH1N1 vaccine
hemagglutinin (HA)
(Fluvirin, Novartis)
127 pregnant HIV
infected women on
antiretroviral therapy
received 2 doses
administered 21 days
apart
Moderately immunogenic with
73% seroprotection after ﬁrst
30 g dose and 80% after
second dose l (less
immunogenic than in studies
with HIV-uninfected pregnant
women)
Seroprotection in infants
waned rapidly: 65% at delivery,
26% at 3 months and 12% at 6
months
[31]
Safety objective: No safety signal in any of the studies.
I her to infant and persistence.
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Fig. 1. The following Research and Development Partners have collaborated to
Advance Maternal Immunization: NIH: National Institutes of Health, including Ofﬁce
of  Research on Women’s Health (ORWH); National Institute of Child Health and
Human Development (NICHD); National Institute of Deafness and Communication
Disorders (NIDCD); National Institute of Allergy and Infectious Diseases (NIAID):
Division of AIDS (DAIDS), Division of Allergy, Immunology and Transplantation
(DAIT), Division of Microbiology and Infectious Diseases (DMID). CDC: Centers for
Disease and Prevention. FDA: Food and Drug Administration, Center for Biologics
Evaluation and Research (CBER). WHO: World Health Organization. Other Govern-
ment Agencies, for example, National Vaccine Advisory Committee (Department
of  Health and Human Services), National Vaccine Program Ofﬁce (Department ofmmunogenicity objective: efﬁcient transplacental transfer of antibodies from mot
IH sponsor: a = DMID, b = NIDCD, c = DAIT, d = DAIDS and NICHD.
b-antibody.
nd human immunodeﬁciency virus type 1 (HIV) have been spon-
ored. The largest number of volunteers participated in studies
onducted in response to the H1N1 inﬂuenza pandemic in 2009
hen there was a critical need to evaluate monovalent vaccines in
regnant women.
A  priority moving forward will be to determine lessons learned
rom completed maternal immunization studies in order to inform
nd improve future endeavors. To accomplish this goal, collabora-
ions have been initiated with the US Food and Drug Administration
FDA), the Bill and Melinda Gates Foundation (BMGF), PATH (for-
erly known as Program for Appropriate Technology in Health),
he World Health Organization (WHO), and the US Centers for
isease Control and Prevention (CDC) to support and publish the
roceedings of conferences focused on maternal immunization
opics (Fig. 1). These proceedings (see Section 4) inform the pub-
ic health community about the safety of immunizing pregnant
omen, and the potential of vaccine immune responses to protect
others and their infants against infectious diseases. Collabora-
ions with FDA have included discussions on preclinical, laboratory,
linical and regulatory issues. Partnerships with pharmaceutical
ompanies have provided assistance for the evaluation of their vac-
ines in pregnant women. This approach is expected to improve
ptake of recommended vaccines in pregnancy in the United States,
nd to encourage maternal immunization efforts in low and mid-
le income countries where there is an extremely high burden of
nfectious diseases in infants.
. Basic and translational studies
Some examples of this bench to bedside strategy that moved
asic research identifying potential antigens into preclinical and
arly translational studies are described in Table 2 and the sections
hat follow. These and similar studies funded by NIH paved the way
or vaccine trials in pregnant women.
.1. Natural history studiesNatural history and epidemiology studies identiﬁed background
ates of expected adverse events (AEs), correlates of natural pro-
ection and potential impact of maternal immunization on disease
pidemiology.Health and Human Services), Walter Reed Army Institute of Research (Department of
Defense). Non-proﬁt organizations, for example, Bill and Melinda Gates Foundation,
PATH, Wellcome Trust.
For example, since 1974, the Division of Microbiology and
Infectious Diseases (DMID) at the National Institute of Allergy
and Infectious Diseases (NIAID) has supported surveillance of
RSV and inﬂuenza in Houston, Texas [1]. Methodology and data
from this surveillance effort were used in the development of a
maternal immunization protocol evaluating an RSV vaccine [2]. A
primary objective of this protocol was to document the effect of
vaccine-induced, transplacentally transferred maternal antibodies
on primary RSV disease in infants through the ﬁrst RSV season.
Surveillance at the Texas Children’s Hospital was used to deﬁne
F.A. Rubin et al. / Vaccine 3
Table  2
DMID maternal immunization research pathway.
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For the pertussis maternal immunization study [20], serologic
assays were conducted in collaboration with Sanoﬁ Pasteur. Studies
to develop assays to test cell-mediated and humoral antibodies forhe beginning and end of the infants’ ﬁrst RSV season. Infants were
ctively monitored for acute respiratory illness at intervals consis-
ent with previous studies. Nasal specimens were processed with
ethods established in the surveillance studies to conﬁrm RSV dis-
ase. The vaccine was well tolerated and immunogenic in mothers,
nd antibodies were transferred to the infants without enhance-
ent of RSV disease.
Several GBS studies funded by DMID have generated data that
ill inﬂuence maternal immunization as a prevention strategy. A
ase-control study of mothers and their infants with early onset
BS disease versus mothers of healthy infants was  conducted in
998–1999 in Houston, Pittsburgh and Seattle. Levels of maternal
BS capsular polysaccharide-speciﬁc antibody measured in mater-
al serum demonstrated that concentrations of >1 g/mL at the
ime of delivery appeared to protect most neonates from early onset
BS type Ia and III disease [3]. This correlate of protection is impor-
ant to guide GBS vaccine development as vaccines move forward
o licensure.
A longitudinal cohort study of non-pregnant women was
onducted to investigate factors associated with vaginal and rectal-
nly acquisition of GBS [4]. Antibody data from this study led to
 GBS type III-TT (tetanus toxoid) conjugate vaccine clinical trial
n non-pregnant women to determine the effect of vaccination on
BS colonization. The vaccine signiﬁcantly delayed the acquisition
f vaginal GBS III colonization and rectal colonization. These data
ndicate vaccination of pregnant women as a potential strategy for
reventing GBS colonization in the vagina and rectum (personal
ommunication). Thus, prevention of GBS colonization in pregnant
omen could be an approach to protecting infants from GBS dis-
ase.
.2. Vaccine antigen identiﬁcation
Bacterial capsule polysaccharides (CPS) have been recognized
s virulence factors that play an important role in pathogenesis.
BS vaccine development at NIAID was focused on CPS antigens.
asic research to elucidate the chemistry of these polysaccharides
esulted in the identiﬁcation of distinct, antigenically unique CPS
tructures for the serotypes associated with GBS disease. Early vac-
ines were prepared using native CPS. In the mid-1980s, pregnant
omen were immunized with a GBS type III CPS [5]. Because
his vaccine was variably immunogenic, conjugate vaccines were
eveloped. Non-pregnant women immunized with a type III GBS
PS-TT conjugate vaccine demonstrated enhanced immunogenic-
ty as compared to uncoupled CPS [6]. In a phase 1 randomized,
ouble-blind, placebo-controlled clinical trial in pregnant women,
he type III GBS CPS-TT conjugate vaccine elicited good levels of
accine-speciﬁc antibody that was functionally active against type
II GBS [7].3 (2015) 6380–6387 6383
Vaccines to protect against Hib had a similar development path.
At the National Institute of Child Health and Human Development
(NICHD) early Hib polysaccharide vaccines were ﬁrst developed
and subsequently efforts continued to develop a polysaccharide-
conjugate vaccines to protect against Hib infections. Hib conjugate
vaccines and/or polysaccharide vaccines were administered to
pregnant women  [8–11]. The vaccines used in these studies were
puriﬁed Hib polysaccharide polyribosylphosphate (PRP) conju-
gated to diphtheria toxoid (PRP-D) and PRP conjugated to a
nontoxic mutant protein of diphtheria toxin (Hemophilus type b
conjugate – diphtheria CRM 197 protein conjugate vaccine [HbOC]).
NIH Small Business Innovation Research (SBIR) and Small Busi-
ness Technology Transfer (SBTT) grants3 provide funds to support
research focused on new technologies that have potential for
commercial products. Biotechnology companies funded by this
mechanism are exploring new antigens/technologies for vaccine
development which may  progress to vaccines for maternal immu-
nization studies.
2.3. Laboratory assays and reagents
Laboratory tests are critical for the advancement of vaccine
candidates through the preclinical and clinical steps along the
maternal immunization research pathway to support vaccine
efﬁcacy. Overall, this includes well-deﬁned, optimized proce-
dures for immunoassays, and the isolation and characterization
of bacteria and viruses. Serologic assays are needed to evaluate
antibody responses to vaccine candidates in basic research, animal
models and clinical studies, and to measure antibodies in sero-
epidemiological studies. Serologic assays used in toxicology studies
support vaccine safety. Although blood is the most common sam-
ple to be tested, antibodies in breast milk were evaluated in several
maternal immunization studies.
For example, DMID has supported the development of labo-
ratory methods used in maternal immunization efforts related to
GBS, inﬂuenza, RSV, Hib, pertussis and S. pneumoniae research. For
GBS studies, the spectrum of work included optimizing recovery
of GBS from clinical specimens [12], characterizing GBS isolates
[13] and measuring the concentration and functionality of GBS
CPS-speciﬁc antibodies [14,15]. For H1N1 inﬂuenza vaccine stud-
ies Southern Research Institute developed serologic assays that
allowed comparisons of concentration and functionality of anti-
bodies between trials of inﬂuenza vaccines in pregnant women
and healthy young adults. For the RSV maternal immunization
study, procedures were developed for isolating and identifying RSV
from clinical samples, measuring vaccine-induced antibodies in
blood and breast milk, and distinguishing immune responses of
the vaccine from RSV infection by Western Blot analysis [2,16].
For the Hib and S. pneumoniae maternal immunization stud-
ies, DMID funded the development of immunoassays to measure
concentration and functionality and used them to test clinical sam-
ples [10,17,18]. Recently, a new human pneumococcal standard
reference serum (007), a critical reagent used in pneumococcal
immunoassays, was  prepared with support from NIAID and the
Center for Biologics and Evaluation Research (CBER) at the FDA
[19].43 https://sbir.nih.gov.
4 The standard 007sp can be obtained from FDA by contacting Mustafa Akkoyunlu,
MD  PhD at the FDA/CBER/OVRR/DBPAP/Laboratory of Bacterial Polysaccharides.
Email: Mustafa.Akkoyunlu@fda.hhs.gov.
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mmune proﬁling of response to whole cell and acellular pertussis
accines are ongoing.5
RSV reagents including strains, human reference sera and cotton
at reagents are provided without charge to the research com-
unity. The following items have been requested by academic
nvestigators, companies and research foundations to support
accine development efforts: (i) RSV A-2 and RSV B-1, well-
haracterized strains manufactured at Walter Reed Army Institute
f Research, funded by an interagency agreement between NIAID
nd the Department of Defense; (ii) RSV reference serum prepared
y Wyeth [21] and partially funded by NIAID; (iii) RSV reference
mmune globulin prepared by Baxter and an anti-RSV panel [22]
eveloped through an interagency agreement between NIAID and
BER; and (iv) cotton rat reagents.6 Although the cotton rat is
onsidered the animal model of choice for RSV studies, its use in
iomedical research had been limited because of the lack of species-
peciﬁc reagents. The current availability of cotton rat reagents
ave provided an important tool for RSV vaccine development for
he study of mechanisms of disease pathogenesis and immunity.
.4. Maternal immunization animal models
The baboon has emerged as an excellent nonhuman primate
odel to evaluate maternal immunization. For RSV [23] and per-
ussis [24], infected infant baboons develop clinical manifestations
hat parallel those in human infants. Maternal immunization stud-
es with baboons have been conducted using Hib [25], pertussis
26] and RSV [27] vaccines. In some studies, female baboons were
rimed with the study vaccine before pregnancy to mimic  the
uman experience. In all studies, females were vaccinated during
regnancy. In addition to assessing the immune response follow-
ng maternal immunization, recent studies included infection of
ewborn animals with live pathogens [26,27]. Endpoints included
easurement of the immune response following vaccination and
rotection of the newborn animals against clinical disease fol-
owing infection. An immune response was detected in mothers
ollowing vaccination [25–27] and offspring of vaccinated mothers
ere protected against infection [26,27]. These results have led to
he use of the baboon maternal immunization model to evaluate a
ew RSV vaccine candidate [28].
The baboon model has also been used to evaluate the immuno-
enicity of a GBS III-TT vaccine [29]. As new GBS vaccine candidates
ecome available, this model could be used to study parameters of
aternal immunization, such as immunogenicity when adminis-
ered to pregnant baboons and transfer of polysaccharide-speciﬁc
ntibodies to infants.
.5. IND-enabling studies
Studies in pregnant women in the United States must be con-
ucted under an Investigational New Drug Application (IND) which
equires documentation that the sponsor has complied with all
equirements in 21 Code of Federal Regulations, Part 312. Devel-
pmental toxicity studies in animals are required as part of the
ND application and must demonstrate no fetal toxicity for vac-
ines to move forward to testing in pregnant women. Dr. Pamela
cInnes (then at DMID/NIAID, and currently deputy director of the
ational Center for Advancing Translational Sciences (NCATS)) and
BER/FDA staff collaboratively developed protocols for develop-
ental toxicity studies in rabbits which have been used for GBS
5 https://www.urmc.rochester.edu/respiratory-pathogens-research-center/
rojects.aspx.
6 These RSV reagents are available by direct request to BEI Resources (https://
ww.beiresources.org).3 (2015) 6380–6387
III-TT vaccine, Hib vaccine, pneumococcal polysaccharide vaccine,
pneumococcal conjugate vaccine, and RSV PRP-2 subunit vaccine.
Results of these studies indicated no reproductive safety signal in
vaccinated animals. A description of the developmental toxicity
study performed with GBS III-TT has been published [30].
3. Clinical studies
3.1. NIH support of maternal immunization studies
Early studies evaluating vaccines in pregnant women were
funded by various NIH contracts supporting programmatic
research (e.g., GBS, respiratory pathogens). In 1991, a contract
was awarded to the Baylor College of Medicine for a Maternal
Immunization Group. More recent maternal immunization studies
were performed through Vaccine and Treatment Evaluation Units
(VTEUs) which are supported by NIAID contracts. The VTEUs, a
nationwide group of institutions that was established in 1962, have
generated data to affect policy regarding important public health
issues.7 When the 2009 H1N1 inﬂuenza pandemic emerged, the
VTEUs were contacted to evaluate safety and the immune response
to various dosing regimens of candidate vaccines in pregnant
women (Table 1). The results of these vaccine trials were made
available within a few months to help public health ofﬁcials deter-
mine the most appropriate dose of vaccine for this vulnerable
population.
The Division of AIDS (DAIDS) at NIAID has supported clinical
networks to conduct vaccine trials in individuals with or at risk for
HIV infection. Currently, NIAID and NICHD fund a network enrolling
HIV-infected pregnant women  as well as HIV-infected or -exposed
children in various clinical studies (the International Maternal Pedi-
atric Adolescent AIDS Clinical Trials Network [IMPAACT]).8 This
network supported a clinical trial of the 2009 H1N1 inﬂuenza vac-
cine in HIV-infected pregnant women [31].
At DMID, a key to success of the maternal immunization pro-
gram has been the management of vaccine trials by a protocol
team with a scientiﬁc lead, a clinical trials specialist, a regula-
tory affairs specialist and a medical monitor who  worked together
with academia and industry. The scientiﬁc lead is a program ofﬁcer
responsible for the planning, implementation and monitoring of
the vaccine trials. The clinical trials specialist works with the pro-
tocol team and investigators to ensure that good clinical practices
are followed during the vaccine trial, which includes scheduling
of clinical monitoring at clinical sites, and often serving as a com-
munications liaison between DMID, the clinical site(s) and industry
partners. The regulatory affairs specialist is responsible for IND sub-
missions to the FDA and coordinating responses to FDA inquiries
with other members of the protocol team. The medical monitor
manages safety monitoring activities for the vaccine trial, includ-
ing but not limited to, scheduling data safety monitoring board or
safety monitoring committee meetings.
3.2. Maternal immunization protocol development
Vaccines must be evaluated in non-pregnant women of child-
bearing age and shown to be safe prior to immunizing pregnant
women. Investigational and licensed vaccines have been evalu-
ated in NIAID-supported maternal immunization trials. The GBS
III-TT vaccine is an example of an investigational vaccine that was
ﬁrst tested in non-pregnant women [6], found to be safe, and then
administered to pregnant women [7].
7 http://www.niaid.nih.gov/about/organization/dmid/researchers/clinical/vteu/
Pages/default.aspx.
8 http://impaactnetwork.org/.
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Protocol design for studies with pregnant women has evolved
ver time. DMID standard protocol templates were modiﬁed in
egards to inclusion/exclusion criteria and safety assessment of
others and their infants. For example:
An obstetric eligibility algorithm used in early studies was  revised
as the American College of Obstetricians and Gynecologists
(ACOG) updated recommendations for prenatal testing.
Prior to 2009, women were enrolled at 30–34 weeks gestation.
However, for inﬂuenza vaccine studies conducted in 2009, enroll-
ment was extended to include women in their second trimester
of pregnancy because of the Advisory Committee on Immuniza-
tion Practices (ACIP) recommendation that all pregnant women
be immunized with inﬂuenza vaccine.
In most studies, pregnant women were randomized to receive the
vaccine under investigation, or an alternative vaccine or placebo.
Occasionally, a non-pregnant group of women was  included as
an additional control group [20].
Pregnancy-speciﬁc toxicity tables for vital signs, laboratory
values and safety assessments of mothers and infants were devel-
oped by a panel of experts as new data were collected and
reviewed [32–34].
A maternal immunization protocol development meeting con-
cluded that in addition to growth (weight, height and head
circumference) different aspects of infant’s neurodevelopment
(motor, social, language) should be assessed during the follow
up. In an effort to assess neurodevelopment various tests were
used in DMID protocols: Bayley III [20], Ireton [35] and Denver
Development tests (2 and 7). Although no problems were found
using these testing procedures, it was unclear which test was
most appropriate. Infant development experts were consulted,
and the consensus was that Bayley III tests were the most stan-
dardized but results are not deﬁnitive until 18–24 months of age.
However, as a practical matter, the latest infant assessment visit
in most maternal immunization studies has generally been at six
or 12 months of age. Depending on a study and the vaccine some
infants were followed up to two years of age.
.3. Maternal immunization protocol objectives
Most DMID-supported maternal immunization studies were
hase II proof of concept trials with evaluation of safety as the high-
st priority. Thus the primary objective was to evaluate systemic
nd local reactogenicity. No safety signal has been detected in any
f these clinical trials in pregnant women.
Secondary objectives include evaluating immunogenicity using
ppropriate methods (e.g., enzyme-linked immunosorbent assay
ELISA], opsonophagyocytosis killing, viral neutralization). At a
inimum, immunogenicity is evaluated by measuring vaccine spe-
iﬁc antibodies in blood samples taken from pregnant women
efore and 3–4 weeks after vaccination. Transplacental transfer
f maternal antibody is determined by comparing the amount of
accine-speciﬁc antibody in the mother’s blood at the time of deliv-
ry to the amount in infant cord blood. Efﬁcient transplacental
ransfer has been found in all studies to date that collected paired
aternal and umbilical cord blood samples. Persistence of mater-
al antibody is determined by measuring vaccine-speciﬁc antibody
n infant serum samples collected after delivery, usually at two and
ix months of age. Persistence has been observed at protocol spe-
iﬁc time intervals in all studies assessing it. In some clinical trials,
reast milk samples were collected from immunized mothers and
accine-speciﬁc antibody documented [2,10].
Additional (usually exploratory) outcome measures included
he effect of maternal immunization on clinical illness in
nfants born to vaccinated mothers and the effect of maternal3 (2015) 6380–6387 6385
immunization on infant immune responses to recommended rou-
tine vaccines (see Table 1).
Additional examples of some study speciﬁc objectives and ﬁnd-
ings are listed below:
• In a clinical trial administering RSV PFP-2 vaccine to pregnant
women, infants were followed through the ﬁrst RSV season after
birth. RSV disease was conﬁrmed by culture and/or serology.
There was no evidence of increased frequency or severity of
RSV256 associated illness in infants from vaccine recipients when
compared to controls [2].
• Lower levels of pneumococcal nasal colonization were detected
in infants of mothers immunized with 23-valent pneumococcal
polysaccharide vaccine as compared to infants of mothers immu-
nized with HbOC [10].
• Infants born to mothers who had received a pneumococcal 9-
valent vaccine were more likely to have otitis media (OM) in
the ﬁrst six months of life than those whose mothers received
placebo. This difference in OM rates did not persist beyond six
months of age. High levels of maternal pneumococcal antibody
at birth may  have suppressed early infant response to their pneu-
mococcal conjugate vaccine-7 (PCV-7) immunization (Prevnar),
resulting in OM [35].
• In a maternal immunization study with pertussis vaccine (Ada-
cel), there were slightly decreased immune responses following
the primary infant series of pertussis immunizations (Pentacel)
compared to controls, but differences did not persist following
the booster [20].
3.4. Inﬂuenza vaccine protocols
Numerous inﬂuenza vaccine studies were conducted in
pregnant and postpartum women (Table 1). These studies evalu-
ated reactogenicity and immunogenicity of inﬂuenza vaccines in a
number of ways: comparing them to other vaccines (TT [36]); to
the vaccines administered in consecutive seasons, or postpartum
[37] or comparing different formulations [38].
In the fall of 2009, as soon as monovalent H1N1 vaccines were
available and initial safety data obtained in healthy adults, mater-
nal immunization studies were initiated. In these studies, pregnant
women were randomized to receive different vaccine dosages to
determine the optimal regimen. Studies with 2009 H1N1 vaccines
were conducted in healthy pregnant women  [39,40] and HIV-
infected pregnant women  [31]. In all these NIH funded studies the
inﬂuenza vaccines tested in pregnant women were found to be safe
and immunogenic.
4. Meetings, workshops and other collaborative efforts to
advance maternal immunization
As part of the integrated efforts to advance maternal immuniza-
tion strategies, NIH uses input from public workshop and other
forums to assist in building a consensus approach. The ﬁrst NIAID
workshop on maternal immunization was  held in 1989 [41]. The
purpose was  to review the safety, immunogenicity, efﬁcacy and
acceptability of immunizations administered to pregnant women
to prevent maternal disease during late pregnancy and to prevent
disease in early infancy.
The Ofﬁce of Research on Women’s Health (ORWH) was estab-
lished in 1990 by Congressional mandate to promote women’s
health research within and beyond the NIH scientiﬁc community.
This ofﬁce held a workshop in 2011 considering barriers and oppor-
tunities in conducting clinical research studies enrolling pregnant
women [42].
Recent national initiatives to promote and advance maternal
immunization include a meeting in 2011 organized by the National
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accine Program Ofﬁce (NVPO), Department of Health and Human
ervices (DHHS), to assess progress in overcoming barriers to
mmunizing pregnant women with inﬂuenza vaccines and to pri-
ritize research and programmatic efforts. Co-sponsors included
COG, CDC, FDA and NIAID. Proceedings were published in a special
ssue of the American Journal of Obstetrics and Gynecology [43].
In 2011 and 2012, DMID organized a series of conferences
o review data from previous trials. The discussions resulted in
tandardization of reference values for vital signs and laboratory
ssessments [32], and consensus related to safety assessments for
others and infants [33,34] which will be incorporated into future
aternal immunization protocols.
DMID convened follow-up meetings in 2013 to discuss barriers
o and opportunities for research in pregnancy including, but not
imited to, design of pharmacokinetics (PK) studies during preg-
ancy, recruitment and retention of pregnant women in clinical
rials, and reporting of congenital anomalies. Executive summaries
rom these conferences were published as a supplement to Clinical
nfectious Diseases (CID) funded by the BMGF [44]. In 2014, a sympo-
ium was devoted to global health and speciﬁc aspects of research
uring pregnancy in low and medium income countries. The major-
ty of information appearing in this special issue of Vaccine was
resented at the conference in 2014. An RSV Vaccine Workshop, in
une 2015, was co-sponsored by CBER and DMID which included a
ession on the development of RSV vaccines for use in pregnancy.
In addition to organizing conferences and workshops, NIH staff
ave participated in and presented at conferences and workshops
rganized by FDA, CDC, NVPO, ACOG, the March of Dimes, and
he BMGF which have been extremely helpful in identifying unre-
olved issues and building consensuses. For example, NIH staff are
ctively involved in the National Vaccine Advisory Committee’s
NVAC’s) Maternal Immunization Working Group, DHHS. NVAC
ecently reviewed the current state of maternal immunization in
he US and formulated speciﬁc recommendations to the Assistant
ecretary of Health in a report adopted by NVAC in 2014 [45].
. Conclusion
NIH has been supporting maternal immunization studies for
ver 35 years. Basic and translational research provided a strong
oundation for clinical studies. No safety signals have been detected
n any of the studies to date. In multiple studies, the immune
esponse to the vaccine was measured and efﬁcient transplacen-
al transfer was  documented, indicating potential protection of
others and their neonates. NIH staff and collaborative partners
esponded rapidly to the H1N1 pandemic by initiating clinical tri-
ls with pregnant women as soon as vaccines were available. These
ompleted studies were able to quickly provide data for policy deci-
ions. By working together with other institutes and ofﬁces at NIH,
HHS agencies and ofﬁces (FDA, CDC, NVPO), WHO, pharmaceu-
ical and biotechnology companies, and non-proﬁt organizations,
here is increased awareness regarding the beneﬁts of maternal
mmunization. Continued efforts are needed to promote maternal
mmunization to protect pregnant women and their infants against
accine-preventable infectious diseases, especially in resource-
imited settings where the burden is high.
In summary, research and development partnerships are essen-
ial for advancing maternal immunization as a strategy for disease
revention in pregnant women and their infants.
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